Nationwide Children's Hospital: Diffuse Intrinsic Pontine Glioma trials
The registry lists 10 Diffuse Intrinsic Pontine Glioma studies with Nationwide Children's Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.
Early Phase 1 2Phase 1 2Phase 2 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNot yet recruitingNCT07644312Phase 2
- Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Not yet recruitingNCT07206849Phase 2
- ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasRecruitingNCT06838676Phase 2
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionRecruitingNCT06333899Early Phase 1
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingNCT05843253Phase 2
- Targeted Pediatric High-Grade Glioma TherapyRecruitingNCT05839379
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsRecruitingNCT05278208Phase 1/2
- PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaRecruitingNCT05096481Phase 2
- A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK FusionRecruitingNCT04655404Early Phase 1
- A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade GliomaActive, not recruitingNCT03605550Phase 1